Endovia Health (EDVA) news

Endovia Health Sciences, - co and Lupvindol finalizing U.S. manufacturing for Cannepil

Endovia Health Sciences - FDA further determined that minor-use status will be maintained through approval of applicable new animal drug application

The U.S. Food and Drug Administration (FDA) has confirmed that minor-use status will be maintained through the approval of applicable new animal drug applications, ensuring continued incentives for the development of treatments for uncommon diseases in major animal species and for minor species.…

Endovia Health Sciences, - Co and Lupvindol to meet FDA on Nov 19, 2026 for Cannepil pre-submission

Endovia Health Sciences, - Cannepil eligible for conditional approval pathway for canine bone cancer pain

Endovia Health Sciences has announced that its product, Cannepil, has been deemed eligible for the conditional approval pathway by regulatory authorities for the treatment of canine bone cancer pain. This development marks a significant step in the company’s efforts to expand its portfolio into…

Endovia Health Sciences - C/M Capital Master Fund commits minimum $1 mln investment in Endovia Health Sciences - SEC filing

Endovia Health Sciences, Inc. (NYSE American: EDVA) has announced the closing of an initial $500,000 secured convertible debt financing from C/M Capital Master Fund, LP, marking the first tranche of a previously disclosed $1 million investment commitment. The funding is intended to support the…